Evidence map›Paper›PMID 42514273›Full record

ArticleLife (Basel, Switzerland)2026

A Candidate Salivary miRNA Panel for Bronchopulmonary Dysplasia in Very and Extremely Low-Birth-Weight Preterm Infants: A Pilot Exploratory Study.

Arailym Abilbayeva, Elmira Bitanova, Iskander Isgandarov, Beibitgul Bizhigitova, Dinara Yelyubayeva, Kristina Kovaleva, Zhanar Akhmetova, Ismira Gassanova, Balaussa Seitkhan, Indira Baibolsynova and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arailym AbilbayevaShortanbayev General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0001-5081-5492
Elmira BitanovaShortanbayev General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0003-3976-9653
Iskander IsgandarovLaboratory of Breeding and Biotechnology, Institute of Plant Biology and Biotechnology, Almaty 050000, Kazakhstan.ORCID 0009-0001-4386-3303
Beibitgul BizhigitovaShortanbayev General Immunology Department, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.
Dinara YelyubayevaDepartment of Highly Dependent Newborns, Center for Perinatology and Pediatric Cardiac Surgery, Almaty 050000, Kazakhstan.ORCID 0009-0007-1268-2001
Kristina KovalevaGenome Centre, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-6173-4636
Zhanar AkhmetovaGenome Centre, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0003-3686-986X
Ismira GassanovaSchool of Pediatrics, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.
Balaussa SeitkhanSchool of General Medicine-2, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0009-0004-6251-5365
Indira BaibolsynovaDepartment of Chemistry, Abai Kazakh National Pedagogical University, Almaty 050000, Kazakhstan.ORCID 0000-0003-2924-4458
Aibek SmagulDepartment of Natural Sciences Pedagogy, School of Education and Humanities, SDU University, Kaskelen 040901, Kazakhstan.
Zhuldyz ZhoshiyevaDepartment of Economics and Planning, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.
Nishankul BozhbanbayevaNeonatology Department, Asfendiyarov Kazakh National Medical University, Almaty 050000, Kazakhstan.ORCID 0000-0002-7487-2472

Funding

Ministry of Science and Higher Education of the Republic of Kazakhstan AP22786227
6 · The paper itself

Abstract

introductionBronchopulmonary dysplasia (BPD) remains the most significant complication of extreme prematurity, affecting long-term respiratory outcomes. Because current diagnostic criteria identify only established lesions at 36 weeks postmenstrual age, early non-invasive biomarkers are needed. This pilot study aimed to identify a candidate salivary miRNA panel associated with BPD risk and to explore its pathogenetic relevance through in silico analysis.

methodsSaliva was collected from 20 preterm infants (10 with BPD and 10 controls), and miRNA expression was profiled using the GeneChip™ miRNA 4.1 Array Plate. Discriminatory performance was explored by ROC analysis within this discovery cohort, together with power and Spearman correlation analyses.

resultsExpression of hsa-let-7b-5p, hsa-let-7c-5p, and hsa-miR-4454 was significantly elevated in the BPD group (

conclusionsIn this pilot study, salivary miRNAs represent a hypothesis-generating candidate biomarker signal for BPD that requires external validation in larger, independent cohorts before any diagnostic or prognostic application can be considered.

Indexed as

biomarkersbronchopulmonary dysplasiaextremely preterm infantsminimally invasive samplingpilot studysalivary miRNAs

Identifiers

PMID42514273
PMCPMC13413207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.